BIOCORP and Novo Nordisk Expands its 2021 Agreement to Commercialize Mallya Smart Sensor in Japan
Shots:
- The new agreement strengthens Novo Nordisk & BIOCORP's collaboration on the development of the Mallya product, announced in Sept 2021. Novo Nordisk will begin selling Mallya in Japan in H1’23
- Mallya is a smart sensor that connects to the Novo Nordisk FlexTouch insulin pens directly & provide access to diabetes patients to use FlexTouch pens for automatically collect and record daily insulin injection data. Patients will be able to view their inj. history and treatment progress in real time
- Novo Nordisk FlexTouch insulin pens are compatible with Mallya. In early 2022, the company launched the first ever smart insulin pens in Japan i.e., NovoPen 6 and NovoPen Echo Plus
Ref: Businesswire | Image: Biocorp
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
